ArticleScientific reports2026
Mesoporous silicon microparticles enhance antiviral immunity and memory responses against SARS-CoV-2.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Silica-based materials have attracted considerable interest as vaccine adjuvants due to their ability to potentiate immune responses. In this study, we evaluated the immunogenicity and protective efficacy of heteromorphous mesoporous silicon microparticles (MSMPs) as an adjuvant in the context of SARS-CoV-2 vaccination. MSMPs conjugated with the S1 subunit of the spike protein (MSMPs-S1) elicited a robust and sustained humoral immune response in BALB/c mice, comparable to that induced by aluminum-based adjuvants. Following a booster dose, MSMPs-S1 significantly increased IgG2a titers and neutralizing antibody levels, surpassing those observed with Al(OH)₃-based formulations. In addition, MSMPs-S1 enhanced cellular immunity, as reflected by higher IFN-γ production in T cells relative to the aluminum-adjuvanted group. In k18-hACE2 transgenic mice, vaccination with MSMPs-S1 conferred protection against a lethal SARS-CoV-2 challenge, resulting in marked reductions in viral loads in both lung and brain tissues. In vitro, stimulation of human peripheral blood mononuclear cells (PBMCs) with MSMPs-S1 increased IFN-γ production in T cells, particularly in the presence of dendritic cells. Collectively, these findings support the potential of MSMPs as an effective adjuvant capable of promoting both humoral and cellular immunity, with relevance for the development of vaccines targeting emerging viral pathogens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.